
1. malar j. 2018 nov 8;17(1):416. doi: 10.1186/s12936-018-2548-2.

assessment drug resistance associated genetic diversity mauritanian
isolates plasmodium vivax reveals limited polymorphism.

mint deida j(1)(2), ould khalef y(3), mint semane e(4), ould ahmedou salem ms(1),
bogreau h(5)(6)(7), basco l(6), ould mohamed salem boukhary a(8)(9), tahar r(2).

author information: 
(1)unité de recherche génome et milieux (jeai), faculté des sciences et
techniques, université de nouakchott al-aasriya, nouveau campus universitaire, bp
5026, nouakchott, mauritania.
(2)unité mixte de recherche 216 mère et enfant face aux infections tropicales,
institut de recherche pour le développement (ird), faculté de pharmacie,
université paris descartes, 4 avenue de l'observatoire, 75270, paris cedex 06,
france.
(3)service de pédiatrie, centre hospitalier mère et enfant (chme), nouakchott,
mauritania.
(4)centre de santé de teyarett, nouakchott, mauritania.
(5)unité de parasitologie et d'entomologie, institut de recherche biomédicale des
armées, ihu-méditerranée infection, marseille, france.
(6)aix marseille univ, ird, ap-hm, ssa, vitrome, ihu-méditerranée infection,
marseille, france.
(7)centre national de référence du paludisme, institut hospitalo-universitaire
(ihu) méditerranée infection, marseille, france.
(8)unité de recherche génome et milieux (jeai), faculté des sciences et
techniques, université de nouakchott al-aasriya, nouveau campus universitaire, bp
5026, nouakchott, mauritania. alimedsalem@gmail.com.
(9)aix marseille univ, ird, ap-hm, ssa, vitrome, ihu-méditerranée infection,
marseille, france. alimedsalem@gmail.com.

background: plasmodium vivax predominant malaria species northern
mauritania. molecular data p. vivax isolates circulating west africa are
scarce. present study analysed molecular markers associated resistance
to antifolates (pvdhfr pvdhps), chloroquine (pvmdr1), artemisinin (pvk12)
in p. vivax isolates collected two cities located saharan zone of
mauritania.
methods: blood samples obtained p. vivax-infected patients recruited
for chloroquine therapeutic efficacy study 2013 febrile patients
spontaneously consulting health facilities nouakchott atar 2015-2016.
fragments pvdhfr (codons 13, 33, 57, 58, 61, 117, 174), pvdhps (codons
382, 383, 512, 553, 585), pvmdr1 (codons 976 1076) pvk12 (codon 552) 
genes amplified pcr sequenced.
results: isolates nouakchott (126/154, 81.8%) atar (44/45,
97.8%) carried wild-type pvdhfr allelic variant (ipfstsi). nouakchott, all
mutants (28/154; 18.2%) double pvdhfr mutations positions 58 61
(allelic variant ipfrmsi), whereas atar 1 isolate mutant (s117n,
allelic variant ipfstni). wild-type pvdhps allelic variant (sakav) found 
in tested isolates (nouakchott, n = 93; atar, n = 37). isolates in
nouakchott (5/115, 4.3%) atar (3/79, 3.8%) mutant pvmdr1 allele 976f 
or 1076l, both, including pre-treatment isolates obtained from
patients treated successfully chloroquine. isolates (59 nouakchott
and 48 atar) carried wild-type v552 allele pvk12.
conclusions: polymorphisms pvdhfr, pvdhps, pvmdr1, pvk12 limited in
p. vivax isolates collected recently nouakchott atar. compared the
isolates collected nouakchott 2007-2009, evidence for
selection mutants. presence one, both, two potential
markers chloroquine resistance pvmdr1 pre-treatment isolates not
influence clinical outcome, putting question role pvmdr1 mutant
alleles 976f 1076l treatment failure. molecular surveillance an
important component p. vivax malaria control programme saharan zone 
mauritania predict possible emergence drug-resistant parasites.

doi: 10.1186/s12936-018-2548-2 
pmcid: pmc6225721
pmid: 30409138  [indexed medline]

